Telomir Pharmaceuticals, Inc. Common Stock (TELO) financial statements and ratios from SEC XBRL: revenue $125644.00 (TTM), net margin -8287.9%, revenue growth 161.8% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $125644.00 |
| Net Margin | -8287.9% |
| Revenue Growth (YoY) | 161.8% |
| EPS Growth (YoY) | -158.9% |
| Price / Book | 15.52 |
| Price / Sales | 732.29 |
| Sector P/E (Healthcare) | 21.7 |
TELO overview · TELO earnings · TELO KPIs · TELO investor relations · TELO ownership · TELO peers · TELO filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.